Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.

Alicja PuszkielGuillaume BianconiBlaise PasquiersDavid BalakirouchenaneJennifer ArrondeauPascaline Boudou-RouquetteMarie-Claire BretagneJoe-Elie SalemXavier DeclèvesMichel VidalNora KramkimelSarah GueganSelim AractingiOlivier Huillard Jérôme AlexandreMarie WislezFrançois GoldwasserBenoit Blanchet

Published in: British journal of cancer (2024)

Clinical trials are warranted to confirm the non-inferiority of extended-interval compared to standard regimen.

Keyphrases

clinical trial
molecular dynamics
monte carlo
phase ii
study protocol
randomized controlled trial